Generalized anxiety disorder (GAD) is usually treated with antidepressant therapy (ADT); however, sometimes ADTs alone are not enough to adequately treat GAD. The purpose of this study is to assess how safe and effective ABBV-932 is when added to the antidepressant therapies in adult participants with GAD who have had an inadequate response ADTs. ABBV-932 is an investigational drug being developed for the adjunctive treatment of GAD. Participants will be randomly assigned to receive ABBV-932 or Placebo in addition to their currently prescribed ADTs. There is 1 in 3 chance of participants assigned to Placebo. Approximately 315 adult participants with GAD and inadequate response to ADTs will be enrolled in approximately 50 sites in the United States and Puerto Rico. Participants will receive oral capsules of ABBV-932 or matching placebo in addition to their prescribed ADT for 6 weeks and then will be followed for an additional 4 week follow-up period. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Generalized Anxiety Disorder (GAD)
Generalized anxiety disorder (GAD) is usually treated with antidepressant therapy (ADT); however, sometimes ADTs alone are not enough to adequately treat GAD. The purpose of this study is to assess how safe and effective ABBV-932 is when added to the antidepressant therapies in adult participants with GAD who have had an inadequate response ADTs. ABBV-932 is an investigational drug being developed for the adjunctive treatment of GAD. Participants will be randomly assigned to receive ABBV-932 or Placebo in addition to their currently prescribed ADTs. There is 1 in 3 chance of participants assigned to Placebo. Approximately 315 adult participants with GAD and inadequate response to ADTs will be enrolled in approximately 50 sites in the United States and Puerto Rico. Participants will receive oral capsules of ABBV-932 or matching placebo in addition to their prescribed ADT for 6 weeks and then will be followed for an additional 4 week follow-up period. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder
-
Viking Clinical Research Center - Temecula /ID# 268598, Temecula, California, United States, 92591
Sunwise Clinical Research /ID# 267863, Walnut Creek, California, United States, 94596
Connecticut Clinical Research - Cromwell /ID# 271241, Cromwell, Connecticut, United States, 06416
Cns Healthcare - Jacksonville /ID# 268588, Jacksonville, Florida, United States, 32256
Accel Research Sites Network - St. Pete /ID# 267821, Largo, Florida, United States, 33777
GMI Florida - Central Miami Medical Institute /ID# 267839, Miami, Florida, United States, 33125-3724
New Hope Clinical Research - Inpatient unit /ID# 267810, Charlotte, North Carolina, United States, 28211
Sooner Clinical Research /ID# 267881, Oklahoma City, Oklahoma, United States, 73116
Grayline Research Center /ID# 267811, Wichita Falls, Texas, United States, 76309
Northwest Clinical Research Center /ID# 267916, Bellevue, Washington, United States, 98007
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to 65 Years
ALL
No
AbbVie,
ABBVIE INC., STUDY_DIRECTOR, AbbVie
2026-11